What is Pacific Biosciences of California Days Inventory?
Pacific Biosciences of CaliforniaPACB +3.12%53 Days Inventory is 188.05 as of Mar. 2026, which is 49% above its 10-year median of 126.17. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Pacific Biosciences of California ranks worse than 54.51% on this metric.
The historical rank and industry rank for Pacific Biosciences of California's Days Inventory or its related term are showing as below:
PACB'
s Days Inventory Range Over the Past 10 Years
Min: 98.9 Med: 126.17 Max: 190.68
Current: 190.68
During the past 13 years, Pacific Biosciences of California's highest Days Inventory was 190.68. The lowest was 98.90. And the median was 126.17.
PACB's Days Inventory is ranked worse than 54.51% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 179.73
vs PACB: 190.68
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacific Biosciences of California's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.49.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacific Biosciences of California's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.35.
Pacific Biosciences of California (NAS:PACB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacific Biosciences of California's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacific Biosciences of California's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pacific Biosciences of California Days Inventory Related Terms
Pacific Biosciences of California Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Days Inventory Chart
PACB vs CATX, LAB, KIDS: Days Inventory Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Days Inventory of 188.05 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pacific Biosciences of California and its competitors. This is 49% above median its historical median of 126.17. Over the past decade, Pacific Biosciences of California's Days Inventory has ranged from 98.90 to 190.68. According to the industry distribution chart, Pacific Biosciences of California ranks #429 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Pacific Biosciences of California's Days Inventory too high?
Pacific Biosciences of California's current Days Inventory of 188.05 is 49% above median its 10-year median of 126.17. Over the past 10 years, this metric has ranged from a low of 98.90 to a high of 190.68. The Medical Devices & Instruments industry median Days Inventory is 179.73. Pacific Biosciences of California's value of 188.05 is 4.6% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #429 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Days Inventory compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #429 out of 787 companies for Days Inventory. This places Pacific Biosciences of California in the lower half of its industry. The industry median Days Inventory is 179.73. Pacific Biosciences of California's value of 188.05 is 4.6% above this benchmark. Historically, Pacific Biosciences of California's own Days Inventory has ranged from 98.90 to 190.68 over the past decade. While the company's 10-year median is 126.17 vs. the industry median of 179.73, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.73, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Days Inventory of 188.05 is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Days Inventory is 188.05, which is 49% above median its own 10-year median of 126.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.65 — trading 1.9% above its estimated fair value. The current Days Inventory is 188.05, which is 49% above median its 10-year median of 126.17 and 4.6% above the Medical Devices & Instruments industry median of 179.73. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Days Inventory is 188.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued.
The current stock price of $1.65 is trading 1.9% above its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Days Inventory: 188.05 (49% above median its 10-year median of 126.17)
GF Value™: $1.62 vs. price of $1.65 (1.9% above fair value)
Industry Position: 4.6% above the Medical Devices & Instruments median (#429 of 787)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
